Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.

Scientific reports - 1 Aug 2017

Chen Qi, Meng Fanyi, Wang Lei, Mao Yong, Zhou Huan, Hua Dong, Zhang Hongjian, Wang Weipeng

Abstract excerpt

To investigate the association of microRNA (miRNA) binding-site polymorphisms in the drug transporter genes with the efficacy of 5-Fluorouracil (5-FU)/capecitabine-based chemotherapy in colorectal cancer (CRC), 6 polymorphisms were determined in 432 CRC patients by using DNA sequencing method. The impacts of the polymorphisms on the miRNA-mediated regulation of gene expression were evaluated by using the methods...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Drug Therapy

Share to Genes, Reporter

Share to Luciferases

Share to Multidrug Resistance-Associated Proteins

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 28765596
DOI: 10.1038/s41598-017-07491-3
PMCID: PMC5539293

Genes

ABCC4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.PMID 28765596Read ↗

Molecular determinants of response to 5-fluorouracil-based chemotherapy in colorectal cancer: The undisputable role of micro-ribonucleic acidsSemantic proximity Read ↗

Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and updateSemantic proximity Read ↗

Repressing PDCD4 activates JNK/ABCG2 pathway to induce chemoresistance to fluorouracil in colorectal cancer cellsSemantic proximity Read ↗

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

The role of ABC transporters in progression and clinical outcome of colorectal cancerSemantic proximity Read ↗

FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10Semantic proximity Read ↗

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.Semantic proximity Read ↗

Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.Semantic proximity Read ↗

Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell linesSemantic proximity Read ↗

Integrative Bioinformatics Analysis: Unraveling Variant Signatures and Single-Nucleotide Polymorphism Markers Associated with 5-FU-Based Chemotherapy Resistance in Colorectal Cancer Patients.Semantic proximity Read ↗

Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.Semantic proximity Read ↗

Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.